KMgCit Superior to KCl for Preventing Thiazide-Induced Hyperglycemia
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Dec. 26, 2023 -- For patients with hypertension without diabetes, potassium magnesium citrate (KMgCit) is better than potassium chloride (KCl) for preventing thiazide diuretic (TD)-induced hyperglycemia, according to a study published in the December issue of Hypertension.
Noting that TDs, which are the first-line treatment for hypertension, can cause excess risk for diabetes, Wanpen Vongpatanasin, M.D., from the University of Texas Southwestern Medical Center in Dallas, and colleagues conducted a double-blinded randomized clinical trial involving 60 patients with hypertension (without diabetes) to compare the effects of 16 weeks of KCl to KMgCit during chlorthalidone treatment. Before randomization, each patient received chlorthalidone alone for three weeks.
The researchers found that chlorthalidone alone induced a significant increase in fasting plasma glucose and significant decreases in serum K, serum Mg, and 24-hour urinary citrate excretion. The rise in fasting plasma glucose was attenuated by 7.9 mg/dL with KMgCit versus KCl. No significant differences were seen between the groups in liver fat.
"These findings suggest that KMgCit may offer a superior alternative to KCl, typically used in clinical practice, in maintaining serum potassium during thiazide-diuretic treatment while avoiding thiazide-induced hyperglycemia," the authors write.
Three authors hold a patent for KMgCit.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2023-12-27 02:15
Read more
- Policies About Late-Career Physicians Are Considered Successful
- How a Move Away From Beef Could Help the Planet
- Private Balcony Hot Tubs Spread Legionnaires Disease on Cruise Ships
- Men Aged >16 to to <55 years at increased risk for acute kidney injury (AKI)
- Racial, Gender, Socioeconomic Disparities Seen in Teen Alcohol, Drug Screening
- FDA Approves Hympavzi for Hemophilia
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions